CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 308 enrolled
Drug / intervention
lacosamidedrug
Likely dose
lacosamide 50mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00522275
NCT00522275Phase 3Completed
CompareCT.gov

An Open-label Extension Trial to Determine Safety and Efficacy of Long-term Oral SPM 927 in Patients With Partial Seizures

UCB BIOSCIENCES, Inc.·interventional·Posted Aug 29, 2007·Updated Jul 18, 2018

In Brief

A Phase 3 clinical trial evaluating lacosamide for Partial Epilepsies. Completed, enrolled 308 participants across 60 sites.

Detailed Summary

The purpose of this trial is to determine whether lacosamide is safe and effective for long-term use in patients with partial-seizures from epilepsy

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPartial Epilepsies
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 29, 2007
Enrollment StartOct 1, 2004
Primary CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 5 yearsPosted 18.8 years ago

Interventions

lacosamidedrug

50mg or 100 mg tablets, up to 800 mg/day given twice daily (BID) throughout the trial